SanegeneBio to Spotlight RNAi Obesity Program and Delivery Platform at TIDES USA 2026

SanegeneBio advanced its positioning in metabolic disease this week as it prepared to showcase its RNA interference, or RNAi, obesity program at the TIDES USA 2026 conference in Boston. The company said CTO and Head of U.S. Operations Dr. Marc Abrams will present its latest RNAi therapeutic data on May 14, 2026, at the leading oligonucleotide and drug-delivery meeting.

SanegeneBio emphasized its proprietary LEAD™ tissue-selective delivery platform as the backbone of its obesity pipeline, highlighting efforts to address limitations of current weight-loss treatments. Management indicated that its RNAi candidates are being designed as potential alternatives or complements to existing obesity therapies, with the goal of improving efficacy and safety profiles.

While specific clinical timelines, regulatory milestones, and financial details were not disclosed, the planned presentation signals ongoing R&D progress and a clear strategic focus on obesity as a priority indication. The company suggested that tissue selectivity may help differentiate its approach in a crowded metabolic disease landscape where durability of effect and tolerability are key.

Participation in TIDES USA is expected to increase SanegeneBio’s visibility among peers, partners, and potential collaborators across the nucleic-acid therapeutics ecosystem. If the preclinical or early clinical data shared at the conference are competitive, they could support future fundraising, business-development discussions, and co-development or licensing opportunities.

From a future outlook perspective, the week’s announcements reinforce SanegeneBio’s intent to compete on both RNAi modality and targeted delivery, areas of high interest for large pharma and biotech partners. Overall, the company used the run-up to TIDES USA to underline its obesity franchise and platform strategy, setting expectations that upcoming data will be an important marker of its progress.